-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: Dr.
Introduction:
During the reporting period, the company invested a large amount of funds for pre-clinical research, clinical trials and preparation of new drugs for the product pipeline
4.
The company is an innovative biopharmaceutical company with excellent independent research and development capabilities as its core driving force.
The company has a founding team and a management team with international innovation vision and deep industry insights
Under the leadership of a management team with rich experience in R&D, production and commercialization, the company has built an integrated biomedical platform, taking into account the needs of R&D quality and R&D speed, and has established a high balance of innovation and risk, covering multiple poles.
The company's product layout focuses on tumors and autoimmune diseases with a broad market space, and focuses on building innovative therapies with synergistic effects
In terms of new drug discovery and development, the company has always adhered to independent innovation as the engine of sustainable development, and has built a compound optimization platform, a drug crystal form research platform, and a research and industrialization platform for insoluble drug solubilization preparation technology: (1) Compounds The optimization platform can accelerate the discovery of highly druggable compounds based on the three-dimensional crystal structure of protein-drug molecules; (2) The drug crystal form research platform can be used to determine the drug substance with dominant crystal forms and support stability studies; (3) Insoluble The research and development and industrialization platform of drug solubilizing preparation technology can solve the bottleneck problem of the current formulations that are common in innovative drugs, and effectively increase the bioavailability of candidate drugs
In terms of clinical research, the company has built a clinical development and registration team centered on China and the United States with excellent program design capabilities, efficient execution capabilities and regulatory communication capabilities
In terms of production, as of March 31, 2021, the company has basically completed the construction of the first phase of the production base in Guangzhou.
In terms of commercialization, as of March 31, 2021, the company has covered hundreds of hospitals across the country, rapidly promoting the market expansion of abutinib in B-cell lymphoma
Reference source: prospectus (application draft)
Reference source: